Case Study
Monday, September 23
10:15 AM - 10:45 AM
Live in Berlin
Less Details
Cell and gene therapy represents a cutting-edge approach in the field of biotechnology, offering revolutionary treatments for a wide range of diseases. The rapid evolution of cell and gene therapy holds great potential for transforming healthcare by providing personalized and curative treatments for patients with previously untreatable conditions. This session delves into the complexities and advancements in the production of these innovative therapies. The manufacturing process for cell and gene therapies is highly specialized, requiring stringent quality control measures, sterile environments, and precise techniques to ensure safety and efficacy. As these therapies continue to show promising results in clinical trials, the scalability and cost-effectiveness of manufacturing processes remain key challenges. In this session we will discuss…
As the Head CMC & Industrialization, PS Biotech & CGT unit at Bayer Pharmaceuticals, Dirk Böhm leads and coaches a cross-functional team responsible for process development, quality, manufacturing, and regulatory aspects of cell and gene therapy products. He has over 20 years of experience in international biotech and pharma manufacturing settings e.g. with Merck Serono and Novartis. With a strong track record of delivering excellent results efficiently and reliably to high quality standards he is passionate of bringing medicines to patients.
His mission is to bring innovative therapies to patients through collaboration and excellence in execution across the Bayer CGT companies and the units in the Bayer group. He is passionate about building efficient teams and organizations, developing talent, and creating a motivating environment. He is also focused on continuous improvement and a clear strategy and direction to bring the best performance year over year. He is an innovation ambassador of the organization, supporting and enabling scouting of external technology and business opportunities.